bioAffinity Technologies Inc (BIAF) FinancialsBIAFbioAffinity Technologies Inc

bioAffinity Technologies Inc (BIAF) generates its revenue primarily from Laboratory services, which accounts for 100.0% of total sales, equivalent to $1.45M. Understanding this concentration is critical for investors evaluating how BIAF navigates market cycles within the Medical Equipment, Supplies & Distribution industry.

Evaluating the bottom line, bioAffinity Technologies Inc maintains a gross margin of 23.91%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -220.77%, while the net margin is -222.83%. These profitability ratios, combined with a Return on Equity (ROE) of -1860.15%, provide a clear picture of how effectively BIAF converts its operational activities into shareholder value.

In the context of the broader market, BIAF competes directly with industry leaders such as XAIR and VVOS. With a market capitalization of $3.56M, it holds a leading position in the sector. When comparing efficiency, BIAF's gross margin of 23.91% stands against XAIR's 12.73% and VVOS's 47.41%. Such benchmarking helps identify whether bioAffinity Technologies Inc is trading at a premium or discount relative to its financial performance.

The company has reported a consistent decline in revenue, with Q1 2026 revenue at $1.35 million, down from $6.2 million in the same period last year. The gross margin is currently at 23.91%, which is relatively low compared to industry standards, and the net income remains negative across multiple quarters.